PWGS_I3137_Developing_an_antimicrobial_strategy_for_sepsis_in_Malawi__DASSIM_-sc-5341
PWGS_I3137_Developing_an_antimicrobial_strategy_for_sepsis_in_Malawi__DASSIM_
DASSIM is an observational study of patients with sepsis admitted to Queen Elizabeth Central Hospital, Blantyre, Malawi. These patients receive prolonged courses of broad spectrum antibiotic, largely ceftriaxone. Blood culture surveillance in Blantyre shows an alarming increase in bloodstream infections with locally untreatable ceftriaxone resistant ESBL producing enterobacteriaeciae (ESBL-E) since ceftriaxone was introduced in 2005, but the drivers of this increase are not clear. DASSIM aims to understand the drivers of acquisition and long term carriage of ESBL-E in sepsis survivors by serial stool sampling and selective ESBL-E culture with subsequent whole genome sequencing of isolates to place them in the local and global context. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
DASSIM is an observational study of patients with sepsis admitted to Queen Elizabeth Central Hospital, Blantyre, Malawi. These patients receive prolonged courses of broad spectrum antibiotic, largely ceftriaxone. Blood culture surveillance in Blantyre shows an alarming increase in bloodstream infections with locally untreatable ceftriaxone resistant ESBL producing enterobacteriaeciae (ESBL-E) since ceftriaxone was introduced in 2005, but the drivers of this increase are not clear. DASSIM aims to understand the drivers of acquisition and long term carriage of ESBL-E in sepsis survivors by serial stool sampling and selective ESBL-E culture with subsequent whole genome sequencing of isolates to place them in the local and global context.